Supreme Court agrees to hear Teva's Copaxone patent case

The Supreme Court will hear a case during its 2014-15 term, which starts in October, regarding Teva's patents on multiple sclerosis drug Copaxone. A reversal of a lower court's ruling would uphold the patents until September 2015, but competitors might introduce generic versions as early as next month. Experts say the case could have far-reaching effects on how patents are interpreted.

View Full Article in:

Bloomberg · New York Times (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
Minneapolis, MN
In house Compliance Officer
Pompano Beach, FL
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC